Eli Lilly and Boehringer Ingelheim Two Pharmaceutical Giants Join the Battle of the Diabetes Epidemic
Eli Lilly is a United States based pharmaceutical company and Boehringer Ingelheim is a German based pharmaceutical based company. The two companies have joined together to “forge the way to a massive expansion in diabetes research, prevention and treatment.”
How the Two Companies will Accomplish There Goal
The two companies plan to co-develop a new type 2 diabetic medication. In addition, the two companies combined have a nice portfolio of compounds that are in the clinical phases of develop they include Boehringer Ingelheim's two oral diabetes agents-linagliptin and BI1077 and Lilly's two basal insulin analogues-LY2605541 and LY2963016. The two companies plan to co-develop and co-commercialize Lilly's anti-TGF-beta monoclonal antibody into a diabetic medication.
Boehringer Ingelheim - Linagliptin and BI10773 Developments
Linagliptin is a dipeptidyl peptidase-4 inhibitor that is currently in the elemental stages of becoming an oral once a day tablet for type 2 diabetics. As of today there are very few once a day medications that last 24 hours. BI10773, a sodium-dependent glucose co-transporter-2 inhibitor that entered into phase 3 clinical trials last year. This medication once completely developed will block the reabsorption of glucose in the kidney. As of this time, there is no medication like this one available.
Eli Lilly - LY2605541 and LY2963016
Both LY2605541 and LY2963016 are basal insulin which are about to enter into phase 3 clinical testing sometime during 2011. Both of these medications will help diabetics with kidney disease.
Together the two pharmaceutical giants have the money, the researchers and the equipment to develop this four and possibly a fifth medication that will give type 2 diabetics another choice of medication to help control their diabetes and even help with kidney disease caused by diabetes.